TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Zacks.com on MSN21h
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & MoreIt was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback